Aescap Venture

Aescap is an Amsterdam-based investment firm established in 2006, specializing in venture capital for life sciences and medical biotech companies in Europe and the United States. The firm focuses on identifying and supporting innovative biotech ventures, aiming to foster growth and development within the industry. Through its investments, Aescap seeks to contribute to advancements in healthcare and medical technologies, positioning itself as a key player in the biotech investment landscape.

Michiel de Haan

Founder and Managing Partner

Patrick Krol

Founder and Portfolio Manager

28 past transactions

F-Star Therapeutics

Post in 2020
F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Orphazyme

Post in 2017
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme

Venture Round in 2017
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

i-Optics

Venture Round in 2015
i-Optics is a medical device company based in 's-Gravenhage, the Netherlands, that specializes in developing innovative corneal diagnostic solutions for eye care professionals. Founded in 2013, the company offers advanced technologies such as the Cassini Corneal Shape Analyzer, which utilizes color LED technology to accurately measure corneal astigmatism, aiding in premium intraocular lens (IOL) planning. This system helps cataract surgeons enhance patient outcomes and reduce unexpected refractive results. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system that employs scanning laser ophthalmoscopy (SLO) to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Through its user-friendly and cost-effective solutions, i-Optics aims to support eye care providers in delivering high-quality care to their patients.

Orphazyme

Series B in 2015
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Avantium

Series G in 2014
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.

F-Star Therapeutics

Series A in 2013
F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Orphazyme

Series A in 2011
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Avantium

Venture Round in 2011
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.

F-Star Therapeutics

Venture Round in 2011
F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

to-BBB

Series B in 2011
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

i-Optics

Series C in 2010
i-Optics is a medical device company based in 's-Gravenhage, the Netherlands, that specializes in developing innovative corneal diagnostic solutions for eye care professionals. Founded in 2013, the company offers advanced technologies such as the Cassini Corneal Shape Analyzer, which utilizes color LED technology to accurately measure corneal astigmatism, aiding in premium intraocular lens (IOL) planning. This system helps cataract surgeons enhance patient outcomes and reduce unexpected refractive results. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system that employs scanning laser ophthalmoscopy (SLO) to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Through its user-friendly and cost-effective solutions, i-Optics aims to support eye care providers in delivering high-quality care to their patients.

Biocartis

Series B in 2010
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Aquapharm Biodiscovery

Series C in 2010
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Affectis Pharmaceuticals

Series D in 2010
Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.

F-Star Therapeutics

Series A in 2010
F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Biocartis

Series A in 2009
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

EOS (Ethical Oncology Science)

Series A in 2009
EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

ActoGeniX

Private Equity Round in 2009
ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Avantium

Venture Round in 2008
Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands. Avantium's proprietary high-throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development. Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields: new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent. Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business. Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.

Vivendy Therapeutics

Series B in 2008
Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

ProtAffin Biotechnologie

Series A in 2008
ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

F-Star Therapeutics

Series A in 2007
F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Aquapharm Biodiscovery

Series B in 2007
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

to-BBB

Series A in 2007
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

ProtAffin Biotechnologie

Series A in 2007
ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

ActoGeniX

Venture Round in 2007
ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Affectis Pharmaceuticals

Series C in 2006
Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.